Immunotherapy Before and After Surgery for MSI-H Colon Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that is stage IIB or III and can be removed with surgery.
- Your tumor must be 'MSI-H' or 'dMMR' — special markers that make it more likely to respond to immunotherapy.
- You are between 18 and 75 years old and your daily activities are not limited (ECOG 0-1).
- You have not had any prior treatment for this cancer (like chemotherapy, radiation, or surgery).
- You have no active infections like tuberculosis or hepatitis B (treated or inactive hepatitis B may be okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new MSI-H/dMMR Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.